Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.61 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378219 | 1.00 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A | |
| Hydrochloric Acid SCHEMBL15688771 | 0.98 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A | |
| SCHEMBL3994717 | 0.88 | SLC1A2 (0.50) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A | |
| SCHEMBL9115232 | 0.85 | SLC1A3 (0.64) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A | |
| SCHEMBL3996075 | 0.85 | CPB2 (0.50) | SLC1A3SLC1A2SLC1A1GABRR1CPB2 | |
| SCHEMBL5592479 | 0.84 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A | |
| SCHEMBL1817121 | 0.83 | SLC1A2 (0.53) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A | |
| SCHEMBL1814055 | 0.83 | SLC1A2 (0.53) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A | |
| SCHEMBL15080320 | 0.81 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A | |
| SCHEMBL622838 | 0.80 | CHRM1 (0.43) | SLC1A3SLC1A2SLC1A1GABRR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102099482-A | Stereoselective enzymatic hydrolysis of 5-methyl-3-nitromethyl-hexanoic acid esters | SANDOZ AG | 2011-06-15 | — | — | CN | claimed |
| EP-0830338-A1 | METHOD OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| WO-1996040617-A1 | METHOD OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4114379-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | Pleopharma, L.L.C. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | ON TARGET THERAPEUTICS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2020185712-A1 | METHODS FOR TREATING SLEEP FRAGMENTATION DISORDERS | ALAIRION, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| CN-105085302-B | Pregabalin intermediate mother liquor and wastewater reuse method | 浙江华海药业股份有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-110072521-A | Pharmaceutical combination comprising a T-type calcium channel blocker | 爱杜西亚药品有限公司 | 2019-07-30 | — | — | CN | disclosed |
| US-20020087017-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | HOGE GARRETT STEWART (US) | 2002-07-04 | — | — | US | disclosed |
| WO-2002048161-A1 | P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-20 | — | — | WO | disclosed |
| EP-1202725-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES | UNIVERSITY OF ROCHESTER (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1180058-A1 | COMBINATIONS OF GABA ANALOGS AND TRICYCLIC COMPOUNDS TO TREAT DEPRESSION | WARNER-LAMBERT COMPANY (US) | 2002-02-20 | — | — | EP | disclosed |
| US-6310098-B1 | PROVIDING GAMMA-BUTYRIC ACID, SALT OR ANALOG WHICH BINDS AN ALPHA2DELTA SUBUNIT OF A VOLTAGE-GATED CALCIUM CHANNEL AND ADMINISTERING ABOVE COMPOUND TO A PATIENT EXPERIENCING HOT FLASHES | UNIVERSITY OF ROCHESTER | 2001-10-30 | — | — | US | disclosed |
| EP-1094803-A2 | USE OF GABA-ANALOGUES FOR TREATING INSOMIA | WARNER-LAMBERT COMPANY (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2001007037-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES | UNIVERSITY OF ROCHESTER (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000061234-A1 | COMBINATIONS OF GABA ANALOGS AND TRICYCLIC COMPOUNDS TO TREAT DEPRESSION | WARNER-LAMBERT COMPANY (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000002546-A2 | USE OF CABA-ANALOGUES FOR TREATING INSOMNIA | WARNER-LAMBERT COMPANY (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | SLC1A3 4446/4885SLC1A2 4649/4885SLC1A1 4551/4885 |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | SLC1A3 4446/4885SLC1A2 4649/4885SLC1A1 4551/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | SLC1A3 4446/4885SLC1A2 4649/4885SLC1A1 4551/4885 |
| US-20020087017-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | PHOSPHO1, BPGM, PHPT1 | SLC1A3 1203/4885SLC1A2 1956/4885SLC1A1 1795/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | SLC1A3 4779/4885SLC1A2 4790/4885SLC1A1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.